A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Ann M. Arvin(VIR Biotechnology (United States)), Katja Fink(Vir Biotechnology (Switzerland)), Michael Schmid(Vir Biotechnology (Switzerland)), Andrea L. Cathcart(VIR Biotechnology (United States)), Roberto Spreafico(VIR Biotechnology (United States)), Colin Havenar‐Daughton(VIR Biotechnology (United States)), Antonio Lanzavecchia(Vir Biotechnology (Switzerland)), Davide Corti(Vir Biotechnology (Switzerland)), Herbert W. Virgin(Washington University in St. Louis)
Cited by 536Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis